iTeos Therapeutics (NASDAQ:ITOS) Stock Price Down 3.7%

iTeos Therapeutics, Inc. (NASDAQ:ITOS)’s stock price traded down 3.7% during trading on Friday . The stock traded as low as $14.84 and last traded at $14.93. 119,275 shares traded hands during trading, a decline of 66% from the average session volume of 355,060 shares. The stock had previously closed at $15.50.

Wall Street Analysts Forecast Growth

ITOS has been the topic of several research analyst reports. HC Wainwright boosted their price objective on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, May 13th. Wedbush restated an “outperform” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research note on Monday, June 17th.

iTeos Therapeutics Price Performance

The stock has a market cap of $536.02 million, a price-to-earnings ratio of -3.87 and a beta of 1.43. The stock’s 50 day simple moving average is $15.03 and its two-hundred day simple moving average is $12.45.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Friday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.05). As a group, analysts predict that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current year.

Institutional Investors Weigh In On iTeos Therapeutics

Several large investors have recently modified their holdings of ITOS. PNC Financial Services Group Inc. boosted its stake in iTeos Therapeutics by 131.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock valued at $25,000 after buying an additional 1,299 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of iTeos Therapeutics by 4,648.4% in the 4th quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after purchasing an additional 2,882 shares in the last quarter. Gladius Capital Management LP grew its holdings in shares of iTeos Therapeutics by 48.7% in the 4th quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock worth $34,000 after purchasing an additional 1,026 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of iTeos Therapeutics by 348.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock worth $45,000 after purchasing an additional 3,216 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in iTeos Therapeutics by 268.5% during the 4th quarter. Signaturefd LLC now owns 4,481 shares of the company’s stock valued at $49,000 after purchasing an additional 3,265 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.